Drugs / dextropropoxyphene
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | DARVON | — | 1957-08-16 | fda.gov ↗ |
Trials 2 · a red edge is where a trial was stopped
1956195719581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00652093 | Mar 2008 → Nov 2010 | lumbar spinal stenosis | University of Rochester | Terminated | No outcome recorded |
| Phase 4 | NCT00378937 | Jan 2004 → Feb 2006 | cancer of unknown primary site | University Hospitals Bristol and Weston NHS Foundation Trust | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dextropropoxyphene | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00378937 ↗ |
| Known as | Propoxyphene | “Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit” NCT00652093 ↗ |
| Route | Oral | “Step 2: Patients in mild-to-moderate pain receive oral codeine or oral dextropropoxyphene hydrochloride 4 times daily and oral acetaminophen 4 times daily.” NCT00378937 ↗ |